Comparative Pharmacology
Head-to-head clinical analysis: CALDOLOR versus JUNIOR STRENGTH IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALDOLOR versus JUNIOR STRENGTH IBUPROFEN.
CALDOLOR vs JUNIOR STRENGTH IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins involved in inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis involved in pain, inflammation, and fever.
800 mg IV every 8 hours as a 30-minute infusion; alternatively, 400 mg IV every 6 hours. Maximum daily dose: 2400 mg.
Oral: 200-400 mg every 4-6 hours as needed; maximum single dose 400 mg, maximum daily dose 1200 mg for OTC use.
None Documented
None Documented
2-4 hours (terminal half-life). Clinical context: Requires dosing every 6-8 hours for sustained effect; no accumulation with normal hepatic function.
Terminal elimination half-life is 2-4 hours in children; prolonged in neonates or hepatic impairment.
Renal (primarily as glucuronide conjugates and inactive metabolites; <10% unchanged). Biliary/fecal elimination is negligible.
Renal excretion of conjugated metabolites (approximately 70-90%) and unchanged drug (<10%). Biliary/fecal excretion accounts for <10%.
Category C
Category D/X
NSAID
NSAID